Interface Biologics Announces New V.P., Business Development
December 04, 2018 08:00 ET
|
Interface Biologics Inc
TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases
November 27, 2018 08:00 ET
|
Interface Biologics Inc
TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical...
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
February 09, 2016 07:30 ET
|
Interface Biologics Inc.;Fresenius Medical Care
TORONTO, CANADA--(Marketwired - Feb. 9, 2016) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Series B Financing Round With DSM and BDC Capital
January 13, 2015 07:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) - Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of...
Interface Biologics and Q3 Medical Devices Sign Agreement to Develop Next Generation Drug Coated Balloon with Kinesyx(TM) Technology
January 14, 2014 07:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) - Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization...
Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General
March 05, 2013 07:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - March 5, 2013) -
Editors Note: There is a photo associated with this press release.
Interface Biologics Inc. (IBI), a privately held...
Interface Biologics Appoints Sandra Beach Lin to Board of Directors
October 02, 2012 07:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - Oct. 2, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Licensing Partner AngioDynamics has Received FDA Clearance for BioFlo(TM) PICC with Endexo(TM) Technology
September 06, 2012 07:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - Sept. 6, 2012) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Interface Biologics Announces Licensing Agreement With Navilyst Medical
October 25, 2011 08:30 ET
|
Interface Biologics Inc.
TORONTO, CANADA--(Marketwire - Oct. 25, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...
Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement
July 12, 2011 08:30 ET
|
Interface Biologics Inc.
TORONTO, ONTARIO--(Marketwire - July 12, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to...